StockData
FibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG) stock

FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 2/30
$0.90−0.02 (-2.56%)

Close on Nov 16, 2026Market cap $6.02MP/E –Yield –

FibroBiologics r&d expenses

Research and development expenses are spending on new products and technology.

FibroBiologics's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.20M, up 28.3% year over year. For fiscal 2025 it was $7.41M, up 64.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.41M+64.5%
FY2024Dec 31, 2024$4.50M+90.2%
FY2023Dec 31, 2023$2.37M+106.5%
FY2022Dec 31, 2022$1.15M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.66M-18.8%
Q1 FY2026Mar 31, 2026$2.95M+65.9%
Q4 FY2025Dec 31, 2025$797.00K-41.2%
Q3 FY2025Sep 30, 2025$2.79M+129.9%
Q2 FY2025Jun 30, 2025$2.04M+109.3%
Q1 FY2025Mar 31, 2025$1.78M+85.4%
Q4 FY2024Dec 31, 2024$1.36M+75.4%
Q3 FY2024Sep 30, 2024$1.21M+112.4%
Q2 FY2024Jun 30, 2024$975.00K+78.2%
Q1 FY2024Mar 31, 2024$960.00K+100.8%
Q4 FY2023Dec 31, 2023$773.00K–
Q3 FY2023Sep 30, 2023$571.00K–
Q2 FY2023Jun 30, 2023$547.00K–
Q1 FY2023Mar 31, 2023$478.00K–

More FibroBiologics figures

See a number that looks wrong?